Modalis Therapeutics Corporation 4883
TSE · Japan · Health Technology
¥32.000.00 (0.00%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Under the agreement, Modalis will be granted rights to utilise EMC181 in the development of MDL-201.
HORSHAM, Pa. & HANGZHOU, China & TOKYO, September 10, 2026--Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883; "Modalis") today announced that they have signed a research collaboration and license agreement to advance MDL-201, an innovative therapeutic candidate for Duchenne muscular dystrophy ("DMD") based on Modalis' proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology. The agreement will become effective on September 14, 2026. Under the agreement, Modalis
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.